OBI Logo.jpg
OBI-992 獲FDA核准展開一/二期臨床試驗
January 03, 2024 05:00 ET | OBI Pharma Inc.
台灣台北電, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技(4174.TWO)今(3)日宣布,旗下以TROP2為標靶、自行研發的抗體藥物複合體(ADC)新藥OBI-992,已獲美國食品藥物管理局(FDA)核准一/二期臨床試驗申請,以評估其安全性及療效。 ...
OBI Logo.jpg
OBI-992 获FDA核准展开一/二期临床试验
January 03, 2024 05:00 ET | OBI Pharma Inc.
台湾台北电, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技(4174.TWO)今(3)日宣布,旗下以TROP2为标靶、自行研发的抗体药物复合体(ADC)新药OBI-992,已获美国食品药物管理局(FDA)核准一/二期临床试验申请,以评估其安全性及疗效。 ...
Sterling-800x800.png
Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening
January 02, 2024 08:00 ET | Sterling Infosystems, Inc
Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening
tiziana-logo.png
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
December 19, 2023 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
Full Logo - OKYO .jpg
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
December 04, 2023 07:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
November 20, 2023 04:00 ET | AKAMPION
- Phase I data show safety and tolerability at clinically significant dose levels- New class of anti-infectives to treat infections with Gram-negative bacteria JERUSALEM, Israel, November 20,...
Emergen logo.png
Medical Devices Testing Services Market Size Worth USD 22.43 Billion in 2032 | Emergen Research
November 15, 2023 12:24 ET | Emergen Research
Vancouver, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The global Medical Devices Testing Services Market will be worth USD 22.43 Billion by 2032, according to a current analysis by Emergen Research. The...
blueberry.JPG
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis
November 13, 2023 02:00 ET | Blueberry Therapeutics
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis Primary endpoint (negative culture and/or clear nail growth) met with 83.3% response rate Secondary...
TLC BioSciences logo.png
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
November 08, 2023 04:54 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
tiziana-logo.png
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
October 18, 2023 07:00 ET | Tiziana Life Sciences Ltd.
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...